Form
Small-molecule tablet
A nonpeptide oral GLP-1 receptor agonist—no self-injection is required.
Clinician-supervised oral GLP-1 care
A simpler path to physician-guided weight management.
A once-daily prescription treatment experience for eligible adults, supported by independent U.S.-licensed clinicians and ongoing monitoring.
Buy NowSecure questionnaire · Pharmacy clinician review required · Individual results vary
1×
Once dailyUse only as prescribed
Licensed U.S. clinicians
Secure health assessment
Ongoing clinical support
Discreet fulfillment
Transparent care pathway
1×
Once-daily tablet when prescribed
0
Self-injections required
Flexible
Take with or without food
72 weeks
Pivotal weight-management study
The science, made practical
Oral GLP-1 care designed for real life.
Orforglipron is a small-molecule, nonpeptide GLP-1 receptor agonist supplied as a once-daily tablet. Treatment is used alongside a reduced-calorie diet and increased physical activity when prescribed for an eligible adult.
5.5 mg is not the universal starting dose. The FDA-approved starting dose is 0.8 mg once daily, followed by stepwise escalation. A licensed clinician must select the appropriate dose. Never take more than one tablet per day.
Routine
Once-daily dosing
Take once daily when prescribed, at the dose selected by the treating clinician.
Flexibility
With or without food
The FDA-approved administration instructions do not require fasting before a dose.
Safety
Stepwise titration
Dose escalation is gradual to help reduce gastrointestinal adverse reactions.
FDA-labeled administration
Simple instructions. Clinical oversight still matters.
- ✓Once daily
- ✓With or without food
- ✓Swallow whole
Evidence in context
The numbers matter. So do the details.
FDA labeling reports results from a 72-week randomized, double-blind, placebo-controlled trial in adults with obesity or overweight and at least one weight-related condition, without type 2 diabetes.
Trial 1 · 5.5 mg group
3,127 adults studied for 72 weeks
All participants received reduced-calorie diet guidance and physical-activity counseling. Results below compare the 5.5 mg group with placebo.
Mean body-weight change
At week 72 in the 5.5 mg group, compared with −2.1% in the placebo group.
Reached at least 5% weight reduction
At week 72 in the 5.5 mg group, compared with 26.8% receiving placebo.
Reached at least 10% weight reduction
At week 72 in the 5.5 mg group, compared with 13.0% receiving placebo.
Study duration
Treatment was studied together with diet and physical-activity intervention.
Results are treatment-group averages from the FDA prescribing information, not a promise of individual outcome. Missing data were statistically imputed as described in the label. Individual results vary.
Read the FDA prescribing information
How it works
Three clear steps. Questionnaire, review, delivery.
Click Buy Now to begin the secure questionnaire. A licensed pharmacy clinician reviews every order before prescription fulfillment.
Complete the secure questionnaire
After clicking Buy Now, share your health history and goals through the pharmacy’s approved intake system.
Pharmacy clinician review
A licensed pharmacy clinician personally reviews your answers and determines whether prescription treatment is appropriate.
Approved orders are fulfilled
When prescribed and approved, the licensed pharmacy prepares the order and coordinates discreet delivery.
Potential treatment option
Daily oral care. No self-injection.
For adults with obesity, or overweight with at least one weight-related condition, when a licensed clinician determines prescription treatment is appropriate.
Prescription only
Oral GLP-1 · Once daily
Orforglipron tablets
A once-daily oral prescription option used with a reduced-calorie diet and increased physical activity. Availability, dose and fulfillment depend on individual clinical evaluation.
Strength shown5.5 mg
Dosage formOral tablet
The image shows a 5.5 mg strength. It is not the universal starting dose. The pharmacy dispenses only the strength prescribed after clinical review.
Program pricing
Shown in intake
before you submit
- ✓Once-daily tablet when prescribed
- ✓Take with or without food
- ✓Clinician-selected dose and titration
- ✓Pharmacy fulfillment only after approval
After the secure questionnaire, a licensed pharmacy clinician reviews each order. Medication ships only when prescribed and approved.
Real patient stories
People who kept going. Real experiences.
Experiences from verified patients. Individual outcomes vary based on starting point, adherence, treatment duration and clinician guidance.
“By month three, I noticed less shedding. By month six, my hair looked fuller around the crown.”
J. M.
Verified patient
“The routine was easy to follow, and over time my hairline began to look fuller and healthier.”
A. R.
Verified patient
Individual results vary. Patient stories do not guarantee similar outcomes. Use only authentic, documented cases with written authorization for every photo and statement.
Built around the patient
Support that continues. Not a one-time checkout.
The experience is designed to keep clinical decision-making, fulfillment and follow-up clearly separated from the public storefront.
Individual
Clinical review
A licensed clinician reviews health information and determines whether treatment is appropriate.
Ongoing
Progress check-ins
Care continues with follow-ups, monitoring and adjustments determined by the clinical provider.
Private
Secure communication
Patient health information stays within the approved clinical care environment.
Do not add before-and-after images or outcome claims unless they are authentic, documented, authorized and reviewed for compliance.
✓
Clinician reviewed
No automatic prescribing
Medical care that is real
A licensed clinician reviews every case.
Eligibility, dose and treatment decisions belong to the independent healthcare professional—not the storefront or an automated sales tool.
✓
Individual clinical decision
Every patient is evaluated according to the provider’s clinical protocols.
✓
Dose management
The treating clinician controls titration, monitoring and any changes to the care plan.
✓
Safety information
Risks, contraindications and adverse effects must be discussed before treatment begins.
BOXED WARNING
Risk of thyroid C-cell tumors
The human relevance of GLP-1 receptor–dependent thyroid C-cell tumors observed in rodents has not been determined. Do not use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Important safety information
Know the risks before treatment.
This summary does not replace the full prescribing information or a conversation with a licensed clinician. Treatment is not appropriate for everyone.
Do not use if
You or a family member has had MTC; you have MEN 2; or you have had a serious allergic reaction to orforglipron or its ingredients.
Serious risks
Warnings include pancreatitis, severe gastrointestinal reactions, acute kidney injury from dehydration, hypoglycemia, serious hypersensitivity, diabetic retinopathy complications, gallbladder disease and pulmonary aspiration during anesthesia or deep sedation.
Common side effects
Nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain or distension, headache, fatigue, burping, reflux, gas and hair loss.
Before starting
Tell the clinician about pregnancy or plans to become pregnant, breastfeeding, severe stomach problems, kidney or liver problems, diabetes medicines, oral contraceptives and every prescription, over-the-counter medicine or supplement you take.
Our care promise
Clear expectations before treatment begins.
Use this section for refund, cancellation and fulfillment commitments that your operating partners have approved in writing.
✓
Eligibility comes first
Prescription care begins only after a licensed clinician determines it is appropriate.
✓
Pricing is disclosed
Patients should see program, medication and recurring charges before enrollment.
✓
Cancellation is clear
Publish the exact cancellation window and refund terms approved by your partners.
Questions answered
Everything you want to know.
These answers are starter copy. Your medical and legal partners should approve every answer before launch.
How does eligibility work?
An independent licensed clinician reviews your health information and decides whether prescription treatment is clinically appropriate.
Is a prescription required?
Yes. Orforglipron is a prescription medication. It should be dispensed only pursuant to a valid prescription through an appropriately licensed pharmacy.
How is the dose selected?
The treating clinician selects and changes the dose based on the approved prescribing information, individual response and tolerability.
What safety information should I review?
Patients should review the current FDA-approved prescribing information and discuss contraindications, warnings, possible adverse reactions and drug interactions with their clinician.
Can everyone use this treatment?
No. Eligibility depends on an individual clinical evaluation. Some medical histories, conditions, medicines or other factors may make treatment inappropriate.
Where is patient health information collected?
Sensitive health information should be collected only in your approved secure clinical platform—not in an ordinary Shopify contact or checkout form.
Start with eligibility
Your next step is a secure clinical assessment.
Learn whether a clinician-guided oral treatment may be appropriate for you.
Buy Now Complete the secure questionnaire after clicking. A licensed pharmacy clinician reviews every order before fulfillment.